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BACKGROUND: Haptoglobin (Hp) -chain alleles 1 and
2 account for 3 phenotypes that may influence the
course of inflammatory diseases via biologically im-
portant differences in their antioxidant, scavenging,
and immunomodulatory properties. Hp1-1 genotype
results in the production of small dimeric, Hp2-1 lin-
ear, and Hp2-2 cyclic polymeric haptoglobin mole-
cules. We investigated the haptoglobin polymorphism
in patients with celiac disease and its possible associa-
tion to the presenting symptoms.
METHODS: We studied 712 unrelated, biopsy-proven
Hungarian celiac patients (357 children, 355 adults; se-
vere malabsorption 32.9%, minor gastrointestinal
symptoms 22.8%, iron deficiency anemia 9.4%, der-
matitis herpetiformis 15.6%, silent disease 7.2%, other
12.1%) and 384 healthy subjects. We determined hap-
toglobin phenotypes by gel electrophoresis and as-
signed corresponding genotypes.
RESULTS: Hp2-1 was associated with a significant risk
for celiac disease (P  0.0006, odds ratio [OR] 1.54,
95% CI 1.20–1.98; prevalence 56.9% in patients vs
46.1% in controls). It was also overrepresented among
patients with mild symptoms (69.2%) or silent disease
(72.5%). Hp2-2 was less frequent in patients than in
controls (P 0.0023), but patients having this pheno-
type were at an increased risk for severe malabsorption
(OR 2.21, 95%CI 1.60–3.07) and accounted for 45.3%
of all malabsorption cases. Celiac and dermatitis her-
petiformis patients showed similar haptoglobin phe-
notype distributions.
CONCLUSIONS: The haptoglobin polymorphism is asso-
ciated with susceptibility to celiac disease and its clini-
cal presentations. The predominant genotype in the
celiac population was Hp2-1, but Hp2-2 predisposed
to amore severe clinical course. The phenotype-depen-
dent effect of haptoglobin may result from the mole-
cule’s structural and functional properties.
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Celiac disease is a genetically determined T lympho-
cyte–mediated chronic inflammatory disorder with an
autoimmune component induced by the ingestion of
wheat gliadin or related rye and barley proteins. Most
affected subjects experience remission after complete
removal of gluten from their diet (1 ). The presence of
human leukocyte antigen (HLA)13-DQ2 or -DQ8 al-
leles appears to be necessary but not sufficient for de-
velopment of disease, and the disease occurs more fre-
quently in females (2 ). Non-HLA genes are estimated
to contribute at least 50% of disease susceptibility, but
the putative risks conferred by other proposed candi-
date genes are substantially lower and controversial
(1, 3). Clinical presentation of the disease is highly
variable, and little is known about what factors deter-
mine its symptoms. Recent epidemiologic studies re-
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vealed that celiac disease affects approximately 1% of
the European and North American populations (4 )
but is underdiagnosed. Increased awareness and the
widespread use of serology tests, however, will lead to
the recognition of more patients with mild symptoms,
and thus to a striking decrease in the duration of symp-
toms and the prevalence of patients with classic malab-
sorption (2 ).
Haptoglobin (Hp) is a potent antioxidant and a
positive acute-phase reaction protein whose main
function is to scavenge free hemoglobin that is toxic to
cells. Hp also exerts direct angiogenic, antiinflamma-
tory, and immunomodulatory properties in extravas-
cular tissues and body fluids. It is able to migrate
through vessel walls and is expressed in different tissues
in response to various stimuli (5 ). Furthermore, Hp
can also be released from neutrophil granulocytes (6 )
at sites of injury or inflammation and dampens tissue
damage locally (7 ). Hp receptors include CD163 ex-
pressed on the monocyte-macrophage system (8 ) and
CD11b (CR3) found on granulocytes, natural killer
cells, and small subpopulations of lymphocytes.Hphas
also been shown to bind to the majority of CD4 and
CD8T lymphocytes (9 ), directly inhibiting their pro-
liferation and modifying the T helper (Th) 1/Th2 bal-
ance (10).
The Hp polymorphism is related to 2 codominant
allele variants (Hp1 and Hp2) on chromosome 16q22,
encoding the Hp -chain, and resulting in 3 major Hp
phenotypes (Hp1-1, Hp2-1, and Hp2-2). TheHp gene
locus consists of 5 exons encoding the 1 allele or 7 exons
encoding the 2 allele. The 2 allele appears to have been
generated from the 1 allele by an intragenic duplication
of exons 3 and 4, presumably via nonhomologous
DNA cross-over. Critical disulfide linkages necessary
for covalent cross-linking of Hp monomers to form
polymers are found in the regions coded by exons 3 and
4. The Hp1 monomer is monovalent and thus creates
dimers. Having a duplicate of exons 3 and 4, Hp2
monomer is bivalent and can associate with 2 different
Hp monomers. Thus homozygous Hp1-1 individuals
expressHp1-1 at the protein level, which is a single1
homodimer with amolecular weight of 86 kDa (Fig. 1).
Homozygous Hp2-2 individuals express the Hp2-2
phenotype, which consists of cyclic Hp polymers con-
taining 3 or more 2 subunits (170–900 kDa). The
haptoglobin molecules synthesized in Hp2-1 hetero-
zygous people are assembled into linear homodimers
and multimers from various numbers of 2 sub-
units flanked by 1 1 subunit at each terminus (86–
300 kDa) (11). Thus the Hp2-1 phenotype is distinctly
different from those produced by the homozygotes for
the Hp2 or Hp1 gene (Fig. 1). The three Hp protein
phenotypes are easily distinguished by gel electro-
phoresis of hemoglobin-enriched serum samples, and
Hp genotypes assigned by this method have shown
complete correspondence with those determined by
PCR from genomic DNA (12).
Phenotype-dependent functional differences exist
in the antioxidant, scavenging, and immunoregulatory
properties of Hp, and the genetic polymorphism of Hp
Fig. 1. Structural differences and subunit arrange-
ment of Hp phenotypes.
Critical disulfide linkages necessary for the covalent cross-
linking of Hp monomers ( subunit) to form polymers are
found on the -chain of the molecule. The Hp1 monomer
(1) is monovalent and thus can only associate with 1
other Hp monomer, whereas the Hp2 monomer (2) is
bivalent and associates with 2 different Hp monomers.
Consequently, the 3 Hp genotypes express entirely different
molecular structures at the protein level. The Hp1-1 mole-
cule is a small homodimer composed of 2 1 subunits (86
kDa). Hp2-2 consists of cyclic polymers carrying different
amount of 2 subunits (170–900 kDa). Finally, the Hp2-1
molecule forms a linear polymer series comprising various
amounts of 2 subunits flanked by 2 1 subunits
(86–300 kDa) at each end. Although theoretically possible,
2 subunits usually do not associate with each other into
cyclic polymers in Hp2-1 individuals owing to the overex-
pression and excess of 1 subunits.
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has been shown to influence the course of a number of
inflammatory and autoimmune diseases (9, 13). Al-
though a cascade of inflammatory events occurs in ce-
liac disease, little is known aboutwhat role theHppoly-
morphism may play in the pathogenesis or clinical
course of celiac disease. A short report in the early
1970s suggested that a higher prevalence of the Hp1-1
phenotype in celiac patients was associated with der-
matitis herpetiformis (14).
The aim of this study was to investigate the distri-
bution of Hp polymorphisms in a large cohort of Hun-
garian celiac disease patients with a broad spectrum of
disease and to evaluate possible associations with clin-
ical presentation.
Materials andMethods
PATIENTS
We studied 712 consecutive, unrelated Hungarian pa-
tients with biopsy-proven celiac disease (357 children
and 355 adults, current median age 17 years [range
2–85], median age at diagnosis 7 years [range 1–85],
male/female ratio 233/479). The control group con-
sisted of 384 healthy, ethnically similar and geograph-
ically matched individuals (median age 38 years [range
17–69], male/female ratio 192/192) who had normal
findings after a thoroughmedical examination that in-
cluded blood pressure measurements and laboratory
tests for celiac disease (antibodies to transglutaminase
[TG]), blood count, serum iron, blood chemistry with
liver and kidney function tests, C-reactive protein, and
thyroid function. The controls were enrolled in the
same clinical centers as the patients and represented
both the western and eastern parts of the country
(Budapest, n 110; West Hungary; n 90, East Hun-
gary; n 184).
The diagnosis of celiac disease was based on small-
bowel biopsy showing severe villous atrophywith crypt
hyperplasia (Marsh type III lesions) (15) and increased
serum levels of antibodies to TG and/or endomysium
(EMA) (16). The EMA and anti-TG tests were used
actively in the participating centers to recognize celiac
disease among patients with suspicious symptoms. IgA
and IgG class EMAwere investigated on human umbil-
ical cord substrate using the indirect immunofluores-
cent method as described (17). Anti-TG antibodies
were measured by ELISA using human recombinant
antigen expressed in E. coli (18, 19). HLA-DQ alleles
were determined in 228 celiac patients from whole
blood samples by PCR with sequence-specific primers
(20). In the absence of initial serology results, we en-
rolled only patients who had a diagnosis confirmed by
traditional gluten challenge (21) and the presence of
HLA-DQ2 or -DQ8 haplotypes.
Dermatitis herpetiformis was diagnosed by direct
immunofluorescence studies of skin biopsy samples
showing granular IgA deposition in the dermal papillae
(22).
We obtained detailed clinical data from clinicians
using a structured questionnaire. Collected data in-
cluded sex, age, and information related to the clinical
disease presentation in the following categories: (a) se-
vere generalized malabsorption (presence of at least
4 of the following 5 symptoms: diarrhea, abdominal
distension, failure to thrive or weight loss, anemia,
hypoproteinemia) or retarded growth; (b) nonspecific
gastrointestinal symptoms that did not compromise
the general condition and somatic development (diar-
rhea, constipation, bloating, recurrent abdominal
pain or vomiting, esophageal reflux); (c) iron defi-
ciency anemia without major gastrointestinal com-
plaints; (d) dermatitis herpetiformis; (e) silent disease
(population screening); (f ) others (autoimmune dis-
eases, reduced bone mineral density, liver disease,
brain disease). Patients were assigned to these major
presentation categories in a prospective manner, based
on clinical findings, routine laboratory results, and
growth chart data at diagnosis.
Informed consent was obtained from all patients
and controls. The study protocol was approved by the
Regional and Institutional Committee of Science and
Research Ethics of the University of Debrecen,Medical
and Health Science Center (DEOEC RKEB/IKEB:
2601–2007).
HAPTOGLOBIN PHENOTYPE/GENOTYPE ANALYSIS
We determined Hp phenotypes in a blinded fashion
from serum samples collected in 2006–2007. SDS-
PAGE was run on 5%–10% gradient gel followed by
immunoblotting using Millipore polyvinyl-difluoride
Immobilon-P transfer membrane (Millipore), poly-
clonal rabbit antihuman haptoglobin, and goat anti-
rabbit horseradish peroxidase antibodies (Dako) in
1:1000 and 1:2000 dilution, respectively, as described
(23). Genotypes were reconstructed by comparison
to Hp1-1 and Hp2-2 manufacturer standards (Sigma-
Aldrich) run in each assay. To evaluate the consistency
of the typing method and that of the expression of Hp
polymers, we also assayed duplicate or triplicate serum
samples taken from the same patients (n 27) in dif-
ferent time points with a median time interval of 12.8
years (range 0.2–14.8 years). All these samples yielded
identical results and indicated the same genotype in all
cases.
STATISTICAL ANALYSIS
Variables were tested for normality with the Shapiro
WilkW test. We used Student t test with separate vari-
ance estimates, 2 test and Fisher exact test to evaluate
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differences between celiac patients and controls.
Within subgroups of celiac patients, we used2 test and
Fisher exact test as appropriate. We used logistic re-
gression to compare genetic and clinical data and ex-
pressed results as odds ratios (ORs) with 95% CI. A
P value of0.05 was considered significant. The statis-
tical analysis SPSS13.0 (SPSS Inc.) was performed by
P.L.L. with the help of a statistician (Peter Vargha).
Results
We assessed the Hp phenotypes and genotypes in a
large cohort of Hungarian celiac patients with diverse
clinical manifestations. Of the 712 patients, 234
(32.9%) presented with severe malabsorption or
growth failure, 162 (22.8%) with nonspecific or minor
gastrointestinal symptoms, 67 (9.4%) with iron defi-
ciency anemia, 111 (15.6%)with dermatitis herpetifor-
mis, and 87 (12.1%) with other symptoms. Fifty-one
(7.2%) patients were recognized through population
screening.
The frequency of Hp2-1 was significantly higher
and that of Hp2-2 was significantly lower in patients
with celiac disease compared with the control popula-
tion and with all groups of historical controls from
different regions of Hungary. In addition, Hp1 allele
was associated with significantly increased risk for ce-
liac disease compared with 2 of the 4 control groups
(Table 1). The Hp phenotype distribution of the
healthy control group was similar to that found in pre-
vious surveys in the normal Hungarian population,
and Hp1 and Hp2 alleles were in Hardy-Weinberg
equilibrium and did not differ with age or sex. Of the
celiac patients, 211 (30%) were from Budapest, 193
(27%) from West Hungary, and 308 (43%) from East
Hungary, but these groups did not show significant
differences.
All celiac patients with available HLA results car-
ried at least 1 copy of DQ2 or DQ8, but the prevalence
of the high-risk DQ genotypes (DQB1*0201/*0201
[DR3;DQ2/DR3;DQ2] or DQB1*0201/*0202 [DR3;
DQ2/DR7;DQ2]) was similar in the 3 Hp groups
(Hp1-1 40.0%, Hp2-1 40.7%, Hp2-2 38.8%). This
finding shows that HLA-related susceptibility markers
were not overrepresented in the Hp2-1 celiac group.
HLA-DQ results were not available for the control
group.
Clinical presentations of celiac disease were dis-
tributed differently in the three Hp genotype groups
(Fig. 2, Table 2). Patients with Hp2-2 presented more
frequently clinically with an increased risk for severe
malabsorption or failure to thrive (OR 2.21, 95% CI
1.60–3.07), and accordingly, less often with only non-
specific or minor gastrointestinal symptoms (OR 0.38,
95% CI 0.25–0.58). Patients with this genotype were
less often clinically silent (OR 0.35 95% CI 0.16–0.76)
than patients in otherHp groups (Table 3). Of all celiac
patients carrying Hp2-2, 44.9% were diagnosed be-
Fig. 2. Clinical presentation of celiac disease in different Hp phenotypes.
DH, dermatitis herpetiformis; GI, gastrointestinal.
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cause of malabsorption or failure to thrive, which was
significantly higher than in celiac patients overall
(32.9%, P  0.0008) or with other Hp genotypes
(26.9%, P0.0001) (Fig. 2). Likewise, 45.3% of all ce-
liac cases that presented with severe malabsorption or
failure to thrive carried Hp2-2 (Table 2), despite the
underrepresentation of Hp2-2 among celiac patients
compared with the general population (Table 1).
In patients who presented with nonspecific or mi-
nor gastrointestinal symptoms and were discovered
through screening, there was a higher prevalence of
Hp2-1 (69.1% and 72.5%) compared with the entire
celiac group, whereas Hp2-2 occurred less frequently
(Table 2).
Dermatitis herpetiformis tended to be more fre-
quent in the Hp1-1 group (22.5%) compared with
other Hp groups (14.8%; P  0.118) or among celiac
patients overall (15.6%; P 0.131), but this difference
was not statistically significant. Only 14.4% of all der-
matitis herpetiformis cases carried Hp1-1, whereas the
majority of this group also had Hp2-1 (Table 2).
The rate of iron deficiency anemia and other clin-
ical symptoms, for disease presentation, were similar
among the three Hp phenotypes, and their distribu-
tion was not found to be different from that of the
entire celiac population. However, the limited num-
ber of subjects in somepatient groupsmay have limited
the statistical power of our studies to detect such
differences.
No correlation was noted between Hp phenotypes
and age at diagnosis. Male/female ratios were found to
be similar in all Hp groups (Table 2).
Discussion
To our knowledge, this is the first report on the role of
Hp genetic polymorphism in relation to disease sus-
ceptibility and clinical presentation in a large cohort of
celiac patients. We applied gel electrophoresis to iden-
tify Hp phenotypes, but it is widely accepted that Hp
phenotypes accurately indicate underlying Hp geno-
types (12). In our study, we found the frequency of
the Hp2-1 phenotype/genotype to be significantly
higher in the Hungarian celiac patients than in Hun-
garian control subjects. Except for one clinical study
dealing with ovarian cancer patients (25), no report
exists on any disease association with the Hp2-1 phe-
notype. Disease associations, in contrast, have been
seen with Hp1-1 (bronchial asthma, atopic dermatitis,
or chronic hepatitis C infection) and Hp2-2 (vascular
complications in diabetic patients, essential hyperten-
sion, or advanced and therapy-resistant tuberculosis).
The few reports on other autoimmune disorders are
based on small patient samples and are often contra-
dictory (26, 27).
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Recent data suggesting thatHp plays amodulating
role on the Th1/Th2 balance may be of interest to
help in understanding celiac disease. The activation of
lamina propria CD4 T cells by gliadin peptides in the
context of HLA-DQ2 or -DQ8 molecule is one of the
key events in the pathogenesis of celiac disease, with
interferon- (IFN-) as the dominant cytokine (Th1
skewed response) (28). Hp promotes a predominately
Th1 cellular response in vitro via an inhibitory effect on
Th2 cytokine release, a finding that has been further
corroborated in vivo, using Hp/ mice (10). These
experiments were carried out with Hp mix purified
from individuals with Hp1-1 and Hp2-1 phenotypes,
but who lacked the Hp2-2 molecule. The Hp1 alleles
were alsomore frequent in a large cohort of Hungarian
patients with Crohn’s disease; this latter group also
showed a higher prevalence of the Hp2-1 phenotype in
the subgroup with inflammatory behavior than the
subgroup that developed strictures (23). Interestingly,
disease-predisposing allele variations in the myosin
IXB gene initially identified in celiac patients were sim-
ilarly found inCrohn’s disease (29), presumably owing
to their proinflammatory properties. Hp1-1 alone, in
contrast, may instead predispose for Th2-associated
diseases, and in vitro, significantly induces greater
amounts of antiinflammatory interleukin (IL)-6 and
IL-10 than Hp2-2 (30).
The association of celiac disease with heterozy-
gotes having both Hp1 and Hp2 alleles is rather un-
usual, and further explanation is needed for the predis-
position of the heterozygous state for disease. It should
be noted that the linear haptoglobin polymers pro-
duced in Hp2-1 individuals differ considerably from
both Hp2-2 and Hp1-1 in their molecular structure,
and may also be functionally different. Both in vitro
and in vivo data support the distinct antioxidant, scav-
Table 2. Distribution of Hp phenotypes among celiac patients with different clinical manifestations.
Hp1-1 Hp2-1 Hp2-2 Total
Celiac disease (total) 71 (10.0) 405 (56.9) 236 (33.1) 712 (100.0)
Male/female 22/49 126/279 85/151 233/479
Mean age at diagnosis, years (SD) 10.79 (10.04) 8.24 (7.86) 8.61 (8.98) 8.61 (8.52)
Clinical presentation
Severe malabsorption/failure to thrive 13 (5.6)a 115 (49.1)a 106 (45.3)a 234 (100)
Nonspecific gastrointestinal symptoms 20 (12.4)b 112 (69.1)b 30 (18.5)b 162 (100)
Iron deficiency anemia 5 (7.5) 39 (58.2) 23 (34.3) 67 (100)
Dermatitis herpetiformis 16 (14.4) 60 (54.1) 35 (31.5) 111 (100)
Other 11 (12.6) 42 (48.3) 34 (39.1) 87 (100)
Silent disease (population screening) 6 (11.8)c 37 (72.5)c 8 (15.7)c 51 (100)
Data are n (%) unless noted otherwise. a P 0.0001, b P 0.0001, c P  0.005 by 2 or Fisher exact test comparing phenotype distribution frequencies between
total celiac disease group and each clinical presentation group.
Table 3. Risk for the development of different clinical presentations among celiac patients with different Hp
genotypes.
Clinical presentation
Hp1-1 vs non–Hp1-1 Hp2-1 vs non–Hp2-1 Hp2-2 vs non–Hp2-2
OR 95% CI P OR 95% CI P OR 95% CI P
Severe malabsorption/failure to thrive 0.43 0.23–0.79 0.005 0.63 0.46–0.86 0.0035 2.21 1.60–3.07 0.0001
Nonspecific or minor gastrointestinal symptoms 1.38 0.80–2.39 NS 1.97 1.35–2.65 0.0004 0.38 0.25–0.58 0.0001
Iron deficiency anemia 0.71 0.27–1.82 NS 1.06 0.64–1.77 NS 1.06 0.62–1.8 NS
Dermatitis herpetiformis 1.67 0.92–3.04 NS 0.873 0.58–1.31 NS 0.92 0.59–1.42 NS
Other 1.36 0.69–2.71 NS 0.67 0.43–1.06 NS 1.34 0.85–2.13 NS
Silent disease (population screening) 1.22 0.50–2.98 NS 2.104 1.12–3.97 0.0192 0.35 0.16–0.76 0.005
ORs were calculated from 4-fold contingency tables and give the odds for patients in each Hp group to present with the given symptom in comparison with the
patients belonging to the other 2 Hp phenotypes. NS, not significant.
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enging, and immunomodulatory properties of differ-
ent Hp phenotypes. Unfortunately, most of the func-
tional studies compared Hp1-1 with Hp2-2, and only a
few studies were applied to purified Hp2-1 (10). Thus,
little is known about real behavior of Hp2-1. Hp2-1
manifests certain features characteristic of both Hp1-1
and Hp2-2. Like Hp2-2, Hp1-1 consists of a series of
polymers with high molecular weights, but it also con-
tains an 1 subunit at each end. These structural fea-
tures may display a behavior similar to either Hp1-1 or
Hp2-2 in certain conditions, whereas opposite behav-
iors may be evident in other conditions. New func-
tional studies are clearly needed to further clarify the
role of Hp2-1 in celiac disease and in the inflammatory
process in general.
The clinical manifestations of celiac disease are
highly variable, and the disease may present either in
childhood or during adult life and may involve multi-
ple organ systems. For certain times in the natural
course of celiac disease, the disease may not be associ-
ated with obvious clinical signs and symptoms (4 ) but
it may later progress to overt disease. Furthermore, the
disease manifestations may also change over time,
making the task of evaluating the factors that contrib-
ute to clinical presentation even more difficult and
challenging. For these reasons, we have used only few,
obviously different and prospectively assigned sub-
groups in our study. We evaluated a sufficiently large
patient cohort in which not only malabsorption pa-
tients, but also cases detected on the basis of screening
tests and other mild forms, were sufficiently repre-
sented owing to the active diagnostic approach in the
clinical centers involved. In this celiac cohort, the fre-
quency of theHp2-2 phenotype was significantly lower
than in the general population (P  0.0023), but pa-
tients with this phenotype showed an increased risk for
generalized malabsorption or failure to thrive. These
severe disease manifestations were once the “classic”
features of the disease, but currently they only repre-
sent the tip of the celiac iceberg (31). At the same time,
Hp2-2 was not associated with the diagnosis at an ear-
lier age, but this could also be explained by the high
number of young children who have been diagnosed
with celiac disease in recent years while the disease is
still relatively mild.
Hp2-2 was rare among celiac patients with non-
specific and mild symptoms or silent disease; rather,
Hp2-1 (69.1%–72.5%) in the group with mild mani-
festations was more prevalent than in the entire celiac
patient group. Given that silent cases are estimated to
be up to 7 times more common than symptomatic
cases (31), this finding further supports the primary
association of celiac disease with Hp2-1. However,
these results need to be reevaluated in other popula-
tions from geographically diverse regions.
The disease-modifying effect of Hp2-2 might be
related to its lower efficacy both in preventing oxidative
tissue damage (32) and to downregulation of the in-
flammatory processes in general. This is also evidenced
clinically in the significant association of Hp2-2 with
vascular complications in diabetic subjects (33). Hp2-
2–hemoglobin complexes are eliminated less effi-
ciently and more slowly via the CD163 receptor than
those complexes that contain Hp1-1. Additionally,
Hp2-2 was independently associated with a significant
decrease in the expression of CD163 (34). The CD163
receptor constitutes the only route for the clearance of
Hp–hemoglobin complexes in extravascular sites.
Thus subjects with Hp2-2might experience higher lev-
els of reactive oxygen species generated in tissues.
Recent data suggest that the CD163 receptor of
macrophages not only functions as a scavenger re-
ceptor for the Hp–hemoglobin complex but also has
an immunomodulatory action with pivotal anti-
inflammatory properties leading to the synthesis of
IL-10, heme oxygenase, and bilirubin (35). It has
been also demonstrated that, upon binding of Hp2-2–
hemoglobin complexes to CD163, significantly lower
amounts of the antiinflammatory IL-10 are released
thanwithHp1-1 (36). IL-10 has an immunoregulatory
effect on gliadin-dependent T-cell activation, inter-
feres with antigen presentation, and induces hypo-
responsive gliadin-specific T cells (37). Hp2-2 is also
associated with stronger immune reactivity, weaker in-
hibitory effect on prostaglandin synthesis (38, 39), and
higher B cell and CD4 T lymphocyte counts in the
peripheral blood (40).
Our patient material included a very large cohort
of patients with dermatitis herpetiformis (15.6% of all
cases). However, we could not confirm the observation
of Marks et al. from 1971 (14) on the higher incidence
of Hp1-1 phenotype in a small cohort of dermatitis
herpetiformis compared with celiac disease patients.
These authors did not publish details on the exact
number of the subjects or on the frequency of Hp phe-
notypes. We found a slightly higher percentage of
Hp1-1 among our 111 dermatitis herpetiformis cases,
but this result was not statistically significant and only
14% of these patients carried Hp1-1, a frequency sim-
ilar to the general population.
In conclusion, the Hp2-1 phenotype was signifi-
cantly more frequent in Hungarian patients with celiac
disease compared with the general population. When
Hp2-2 was present, it predisposed to a more severe
clinical course. These findings suggest a role for Hp
polymorphism or related polymorphisms in disease
susceptibility and modification in celiac disease. Our
data also call for additional basic research on Hp in
innate and adaptive immunity.
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